Last reviewed · How we verify
DA-9701
DA-9701 enhances gastric motility and accelerates gastric emptying by acting as a dopamine antagonist and acetylcholinesterase inhibitor.
DA-9701 enhances gastric motility and accelerates gastric emptying by acting as a dopamine antagonist and acetylcholinesterase inhibitor. Used for Functional dyspepsia, Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | DA-9701 |
|---|---|
| Also known as | Motilitone, Motilitone placebo |
| Sponsor | Seoul National University Hospital |
| Drug class | Prokinetic agent |
| Target | Dopamine receptor antagonist; acetylcholinesterase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
DA-9701 works through dual mechanisms: it blocks dopamine receptors (which inhibit gastric contractions) and inhibits acetylcholinesterase (which increases acetylcholine availability to promote gastric muscle contractions). This combination enhances gastric muscle function and accelerates the movement of food from the stomach into the small intestine, improving gastric emptying.
Approved indications
- Functional dyspepsia
- Gastroesophageal reflux disease (GERD)
Common side effects
- Diarrhea
- Abdominal pain
- Nausea
- Headache
Key clinical trials
- The Effect of Two Prokinetics in Patients With Functional Dyspepsia (NA)
- Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms (PHASE4)
- Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease (PHASE4)
- Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers (PHASE1, PHASE2)
- Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-9701 CI brief — competitive landscape report
- DA-9701 updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI